Wealth Enhancement Advisory Services LLC Takes $354,000 Position in Progyny, Inc. (NASDAQ:PGNY)

Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 15,855 shares of the company's stock, valued at approximately $354,000.

Several other institutional investors have also recently made changes to their positions in PGNY. Voya Investment Management LLC lifted its holdings in Progyny by 1.4% in the 4th quarter. Voya Investment Management LLC now owns 51,792 shares of the company's stock valued at $893,000 after purchasing an additional 701 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock worth $25,000 after acquiring an additional 1,355 shares during the period. F M Investments LLC boosted its position in shares of Progyny by 13.0% during the 4th quarter. F M Investments LLC now owns 20,420 shares of the company's stock valued at $352,000 after acquiring an additional 2,342 shares during the last quarter. First Trust Advisors LP boosted its position in shares of Progyny by 13.1% during the 4th quarter. First Trust Advisors LP now owns 24,105 shares of the company's stock valued at $416,000 after acquiring an additional 2,794 shares during the last quarter. Finally, Covestor Ltd boosted its position in shares of Progyny by 69.4% during the 4th quarter. Covestor Ltd now owns 6,868 shares of the company's stock valued at $118,000 after acquiring an additional 2,814 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company's stock.

Insider Buying and Selling

In related news, Director Cheryl Scott sold 2,675 shares of the firm's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total transaction of $59,037.25. Following the completion of the transaction, the director directly owned 14,112 shares in the company, valued at $311,451.84. This trade represents a 15.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 9.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on PGNY shares. Canaccord Genuity Group decreased their target price on shares of Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Leerink Partners raised shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price target on the stock in a research report on Tuesday. BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective for the company in a research report on Monday, March 31st. Finally, Leerink Partnrs raised Progyny from a "hold" rating to a "strong-buy" rating in a research note on Tuesday. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $24.09.

Progyny Trading Down 1.7%

PGNY traded down $0.40 on Friday, hitting $23.21. The company had a trading volume of 739,927 shares, compared to its average volume of 1,715,109. The firm has a market cap of $1.99 billion, a P/E ratio of 40.72, a PEG ratio of 2.50 and a beta of 1.31. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $30.42. The company's fifty day moving average price is $21.81 and its 200 day moving average price is $21.47.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). Progyny had a net margin of 4.33% and a return on equity of 10.90%. The firm had revenue of $324.04 million for the quarter, compared to analysts' expectations of $307.86 million. During the same quarter last year, the business earned $0.17 earnings per share. The business's revenue was up 16.5% compared to the same quarter last year. On average, analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.